Report on the future of the All Wales Medicines Strategy Group

Published today is a report commissioned by the Welsh Government on the future of the All Wales Medicines Strategy Group (AWMSG) by engaging with a range of key stakeholders. The terms of the review were to consider, review and report on: the role of AWMSG in supporting the future delivery of Welsh Government and NHS Wales’ priorities; the current relationship between AWMSG and NICE in light of plans to expand NICE’s appraisal role; the balance between various functions carried out by the AWMSG, for example between appraisal of new medicines and optimising medicine use; an understanding of how current funding reflects the balance of functions and whether this reflects priorities now and for the future; value for money and scope for efficiencies; organisational governance and scrutiny, and the effectiveness of the current hosting arrangements within Cardiff and Vale UHB; effectiveness, outputs and benefits; and AWMSG’s capacity and capability, both in terms of staffing and leadership, to respond effectively to future demands and the changing environment.

Report on the future of the All Wales Medicines Strategy Group